<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114421">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02039167</url>
  </required_header>
  <id_info>
    <org_study_id>OVGU-014-Kar</org_study_id>
    <nct_id>NCT02039167</nct_id>
  </id_info>
  <brief_title>Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease</brief_title>
  <acronym>WatchAFIB</acronym>
  <official_title>WATCH Bleeding Episodes After Left Atrial Appendage Occlusion Versus Usual Care in Patients With Atrial FIBrillatIon and Severe to eNd-stage Chronic Kidney Disease (WatchAFIB in CKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of left atrial appendage occlusion
      in comparison to oral anticoagulation with a vitamin K antagonist (INR 2-3) related to the
      frequency of occurrence of at least one bleeding classified as moderate or major within 24
      months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, randomized, controlled, multicenter clinical investigation. Transesophageal
      echocardiography (TEE) for all patients within 14 days of the Enrolment Visit. Patients
      randomized to oral anticoagulation (OAC) will receive standard of care (SOC) vitamin K
      antagonist treatment throughout the 24 months clinical investigation period, managed by the
      primary care physician, with the goal of achieving and maintaining an INR of 2-3 (INR
      monitoring by the primary care physician every two weeks throughout study period).

      Patients randomized to the WATCHMAN device will undergo device implantation within 48 hours
      of the screening TEE and after confirmation of INR ≤ 1.7 in the catheterization laboratory
      with a subsequent hospitalization for 24-48 hours.

      Concomitant treatment with Aspirin/Clopidogrel (managed by the patient's primary care
      physician) will be initiated on the day prior to device implantation, and will be continued
      for 6 months after the procedure, at which time Clopidogrel will be discontinued;
      administration of Aspirin will be continued indefinitely.

      Follow-up visits for all patients will take place on Day 45, and at Month 6, Month 12 and
      Month 24 (End of Study). Routine safety and efficacy assessments at each visit will be the
      same for all patients regardless of treatment group.

      Follow-up- visits at day 45, months 6, 12 and 24. Patients randomized to the WATCHMAN device
      will have additional TEE imaging performed at the Day 45 and Month 6 visits.

      An independent Data Monitoring Committee will monitor safety. A blinded and independent
      Endpoint Committee will evaluate end-points throughout the entire study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Frequency of occurrence of moderate and major bleedings (Type 2 to Type 5 according to the Bleeding Academic Research Consortium (BARC) definitions)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of at least one occurrence of a combined endpoint of moderate or major bleeding and/or severe cardiovascular adverse events (stroke, cardiac infarction, thrombosis, death)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to occurrence of first moderate and major bleeding as well as to occurrence of stroke (ischemic or hemorrhagic) according to the modified Rankin scale</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Blood Coagulation Disorders</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Thrombosis of Left Atrial Appendage</condition>
  <condition>Chronic Kidney Disease Stage 4</condition>
  <condition>Chronic Kidney Disease Stage 5</condition>
  <arm_group>
    <arm_group_label>Left atrial appendage occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous left atrial appendage closure using the WATCHMAN device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAC with a vitamin K antagonist</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left atrial appendage occlusion</intervention_name>
    <description>Percutaneous left atrial appendage closure using the WATCHMAN device.</description>
    <arm_group_label>Left atrial appendage occlusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF),
             documented by electrocardiography performed at screening or within the prior 6 months

          -  Indication for oral anticoagulation as assessed by CHA2DS2-VASc-Score (≥ 2)

          -  Severe to end-stage chronic kidney disease (eGFR &lt; 30 ml/min as determined by the
             Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)

          -  18 to 80 years, inclusive

          -  Life expectancy of at least 2 years

          -  Negative pregnancy test for women

          -  Capable of understanding the investigational nature, potential risks and benefits of
             the study, and able to provide valid informed consent

          -  Written informed consent

        Exclusion Criteria:

          -  AF due to a reversible cause or a singular occurrence of AF

          -  Conditions other than AF that require anticoagulation

          -  Transient ischemic attack or stroke within previous 3 months

          -  A need for Aspirin (at a dose of &gt; 162.5 mg/day) or for both Aspirin and
             Clopidogrel/other antiplatelet drugs (daily administration) other than for clinical
             investigation

          -  Contraindications or allergies to vitamin K antagonists, Aspirin or Clopidogrel

          -  Previous closure (surgical, interventional) of the left atrial appendage (LAA)

          -  Previous closure of atrial septal defect (ASD) / persistent foramen ovale (PFO)

          -  Active internal bleeding

          -  Thrombocytopenia (&lt; 100,000 platelets/mm3)

          -  History of or planned organ transplantation

          -  Planned Mitra Clip or transcatheter aortic valve implantation (TAVI) intervention

          -  Planned cardiac surgery

          -  History of intracranial, intraocular or retroperitoneal bleeding

          -  Severe GI-bleeding within the last 3 months

          -  Hemorrhagic gastro-intestinal diseases (e.g., ulcerative colitis)

          -  History of or condition associated with increased bleeding risk

          -  Uncontrolled arterial hypertension

          -  Heparin-induced thrombocytopenia type II

          -  Known inherited coagulation disorders

          -  Severe liver dysfunction (spontaneous INR &gt; 1.5) or liver cirrhosis ≥ CHILD B

          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Women who are planning to become pregnant, or who are breastfeeding

          -  Active infection of any kind

        Transesophageal echocardiography (TEE) Exclusion Criteria

          -  Intracardiac thrombus or dense spontaneous echo contrast as visualized by TEE (with
             use of sonovue in suspicious cases)

          -  Significant mitral valve stenosis

          -  Any congenital heart disease, including atrial septal defect

          -  Pericardial effusion during ECHO assessment of &gt; 2 mm

          -  Cardiac tumor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rüdiger C Braun-Dullaeus, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-von-Guericke University Magdeburg Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas P Rauwolf, Dr</last_name>
    <phone>++49 391 6713203</phone>
    <email>thomas.rauwolf@med.ovgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Otto-von-Guericke University Magdeburg, Faculty of Medicine</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas P Rauwolf, Dr</last_name>
      <phone>++49 0391 6713203</phone>
      <email>thomas.rauwolf@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Schmeißer, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Friederike Großmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Said, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave Wenzel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Rauwolf, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rüdiger C Braun-Dullaeus, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka - Klinik für Kardiologie</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernward Lauer, Prof.</last_name>
      <phone>+493645851201</phone>
      <email>bernward.lauer@zentralklinik.de</email>
    </contact>
    <investigator>
      <last_name>Bernward Lauer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Geller, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCB im Markus Krankenhaus Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris H Schmidt, Dr</last_name>
      <phone>+4969951548159</phone>
      <email>b.schmidt@ccb.de</email>
    </contact>
    <investigator>
      <last_name>Stefano Bordignon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Fürnkranz, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris H Schmidt, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Chun, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Zentrum Innere Medizin, Abt. Kardiologie und Angiologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antje Jürgens</last_name>
      <phone>+49511532 6054</phone>
      <email>Juergens.Antje@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>David Duncker, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Hohmann, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thorben König, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanno H Oswald</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrik S Schreyer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Sedding, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Veltmann, PD Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 19, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Prof Dr Ruediger C. Braun-Dullaeus</investigator_full_name>
    <investigator_title>Prof Dr</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
